RT Journal Article
SR Electronic
T1 Pre-existing anti-polyethylene glycol antibodies in pregnant women and newborns
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.29.24317450
DO 10.1101/2024.11.29.24317450
A1 Wang, Haiyang
A1 Feng, Yan
A1 Zhang, Lin
A1 Yuan, Changzheng
A1 Xue, Junyang
A1 Li, Jicheng
A1 Xu, Xiao
A1 Zhou, Wenbin
A1 Li, Baohua
A1 Wang, Yisha
A1 Luo, Gan
A1 Zheng, Yue
A1 Sui, Meihua
YR 2024
UL http://medrxiv.org/content/early/2024/12/10/2024.11.29.24317450.abstract
AB Importance Pre-existing anti-polyethylene glycol (PEG) antibodies represent risk factors for reduced efficacy and increased adverse reactions in seropositive individuals receiving PEGylated drugs, but neither their sero-prevalence, nor levels nor potential influencing factors have been investigated in pregnant women or newborns.Objective To parallelly determine the sero-prevalence and levels of pre-existing anti-PEG antibodies in pregnant women and newborns, and to reveal their independent influencing factors.Design Cross-sectional analysis using data of pregnant women and their newborns enrolled between May 2021 and May 2022.Setting Pregnant women admitted for delivery at the Women’s Hospital, Zhejiang University School of Medicine in China, were approached for enrollment.Participants Participants included 256 pregnant women (volunteers) and corresponding 256 newborns. Major eligibility criteria for pregnant women included an age of 20 years or older, a singleton pregnancy, a full-term pregnancy, no history of unhealthy lifestyle (e.g. smoking, drinking and drug abuse), no contagious disease and no disease requiring drug treatment upon enrollment.Exposures Maternal and cord blood samples were collected around or immediately after the delivery for further examinations, along with questionnaire interviews, demographic and clinical data collections.Main Outcomes and Measures All blood samples underwent screening and quantification of pre- existing anti-PEG antibodies. Sero-prevalence and levels of total anti-PEG antibodies and each known isotype/subclass were determined. Influencing factors for sero-prevalence and levels of pre- existing anti-PEG antibodies in pregnant women and newborns were respectively revealed with in-depth statistical analysis.Results Seropositivities of total anti-PEG antibodies, anti-PEG IgG1 and IgG2, anti-PEG IgM, and coexistence of anti-PEG IgM and IgG were 19.14%, 2.34%, 7.03%, 10.94% and 1.17%, respectively in pregnant women, and 5.47%, 2.73%, 2.73%, 0% and 0%, respectively in newborns. Anti-PEG IgG3, IgG4 and IgE were undetectable in both pregnant women and newborns. Seropositive pregnant women had a median (Range; IQR) anti-PEG IgG1, IgG2 and IgM concentrations of 273.88 ng/mL (183.74-513.90; 191.70-376.08), 748.35 ng/mL (75.54-2604.89; 159.09-1200.81) and 175.07 ng/mL (55.43-23649.14; 95.95-315.19), respectively. Seropositive newborns had a median (Range; IQR) anti-PEG IgG1 and IgG2 concentrations of 207.92 ng/mL (120.40-1513.98; 133.97-524.58) and 336.52 ng/mL (100.24-1069.62; 275.80-527.07), respectively. Furthermore, we revealed that maternal age, take-out food consumption and cosmetic use were influencing factors of prevalence and levels of maternal anti-PEG antibodies, while prevalence or levels of newborn anti-PEG antibodies were affected by maternal age and cosmetic use.Conclusions and Relevance A proportion of pregnant women and newborns were found seropositive for pre-existing anti-PEG antibodies, raising efficacy and safety concerns over the use of PEGylated drugs in pregnant women and newborns/infants. Several influencing factors on maternal and/or newborn pre-existing anti-PEG antibodies were discovered, providing valuable information for deeper understandings on the induction of risky pre-existing anti-PEG antibodies. Specifically, our data suggest that anti-PEG antibodies may be induced by gastrointestinal exposure to PEG antigens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Zhejiang Provincial Natural Science Foundation of China (LZ23E030003 to Dr. Meihua Sui), National Natural Science Foundation of China (21722405 and 22075243 to Dr. Meihua Sui) and Startup Foundation for Hundred-Talent Program of Zhejiang University (to Dr. Meihua Sui).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This cross-sectional study carefully followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines and was approved by the Ethics Committee of Women's Hospital, Zhejiang University School of Medicine (approval No. IRB-20210139-R).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript